Labcorp Announces Board Member Retirement

Labcorp Holdings ( (LH) ) has provided an update.

On December 10, 2025, Labcorp Holdings announced the retirement of Dr. D. Gary Gilliland from its Board of Directors, effective December 31, 2025. Dr. Gilliland, who has been a director since 2014, played a crucial role in the company’s growth and innovation in oncology and gene therapy, significantly contributing to Labcorp’s position as a trusted leader in laboratory services.

The most recent analyst rating on (LH) stock is a Buy with a $287.00 price target. To see the full list of analyst forecasts on Labcorp Holdings stock, see the LH Stock Forecast page.

Spark’s Take on LH Stock

According to Spark, TipRanks’ AI Analyst, LH is a Outperform.

Labcorp Holdings demonstrates strong financial performance and strategic growth initiatives, particularly in the Diagnostics and Central Laboratories segments. While technical indicators suggest a bearish trend, the company’s focus on high-growth areas and technological innovation provides a positive outlook. Valuation metrics indicate the stock is fairly valued, with potential for growth if earnings continue to improve. Recent corporate events further support the company’s strategic direction.

To see Spark’s full report on LH stock, click here.

More about Labcorp Holdings

Labcorp Holdings Inc. is a global leader in innovative and comprehensive laboratory services, providing diagnostics and drug development capabilities. The company supports doctors, hospitals, pharmaceutical companies, researchers, and patients in making informed decisions, serving clients in approximately 100 countries with nearly 70,000 employees.

Average Trading Volume: 774,344

Technical Sentiment Signal: Buy

Current Market Cap: $21.55B

Learn more about LH stock on TipRanks’ Stock Analysis page.